Dupixent Lymphoma MDL Leadership: What Early-Stage Litigation Means for Patients

Where the Dupixent Litigation Stands

Lawsuits filed against Sanofi and Regeneron over Dupixent (dupilumab) and cutaneous T-cell lymphoma (CTCL) were centralized in June 2026 into MDL 3180 in the District of New Jersey. AboutLawsuits.com has reported that plaintiffs’ attorneys are now seeking leadership positions in that MDL.

That may sound like inside-baseball, but it tells patients something useful: this litigation is at its very beginning. Very little has been established as fact. No bellwether trials have taken place, and no court has decided whether Dupixent causes, accelerates, or masks any lymphoma.

This post explains what the leadership stage involves, what the lawsuits allege, and what it means for people who are trying to decide whether to come forward.

Centralization Is Not a Finding About the Drug

The Judicial Panel on Multidistrict Litigation centralizes cases when many lawsuits share common factual questions. Its job is to make the litigation efficient: one judge handling discovery and pretrial rulings instead of dozens of judges duplicating work.

The Panel’s decision to centralize Dupixent cases is not a finding that Dupixent caused anyone’s cancer. It is not a ruling on the merits of any claim. It is a case-management step, and it should be read that way.

The MDL is assigned to the U.S. District Court for the District of New Jersey, where the transferee judge will oversee pretrial proceedings.

What Leadership Appointments Actually Do

In most MDLs, the presiding judge appoints a small group of attorneys to coordinate the plaintiffs’ side. These roles commonly include lead counsel, a steering committee, and liaison counsel. According to reports, attorneys have applied for these roles in the Dupixent MDL; we have not seen a final appointment order cited in the headlines we reviewed.

Once appointed, leadership typically handles work that affects every case, such as:

• Negotiating discovery of the manufacturers’ internal documents and safety data
• Retaining experts on dermatology, oncology, and pathology
• Briefing common legal questions, such as preemption or general causation
• Proposing schedules for fact sheets, records collection, and any eventual bellwether process

Individual plaintiffs keep their own attorneys. Leadership does not replace your lawyer; it coordinates the shared work so that each case does not have to reinvent it.

The Two Theories the Lawsuits Allege

The complaints plead two separate theories, and both matter. Each is an allegation under examination, not a proven mechanism.

First limb: causation or acceleration. Plaintiffs allege that Dupixent may cause a cutaneous T-cell lymphoma, or may accelerate one that was developing.

Second limb: masking and delayed diagnosis. Plaintiffs also allege that Dupixent may mask the early symptoms of a lymphoma the patient already had. On this theory, a patient’s rash may have seemed to improve on treatment while an underlying CTCL went undiagnosed, delaying the biopsy and diagnosis that could have come sooner.

Sanofi and Regeneron dispute these allegations. Whether either theory holds up will be tested through expert evidence, pretrial rulings, and, possibly, trials.

Diagnosed Before Starting Dupixent? You Are Not Automatically Excluded

Many people assume that if their lymphoma was present, or even diagnosed, before they began Dupixent, they have no claim. Under the masking theory, that is not automatically true.

The second limb specifically concerns patients whose lymphoma may have pre-dated treatment. If you were diagnosed with mycosis fungoides or Sézary syndrome before, during, or after Dupixent treatment, the timing is something an attorney should review with your records rather than something you should rule out on your own.

Why CTCL Is Hard to Diagnose

The National Cancer Institute describes mycosis fungoides and Sézary syndrome as types of cutaneous T-cell lymphoma, cancers of T-cell lymphocytes that primarily affect the skin. Early mycosis fungoides can appear as red, scaly, itchy patches that may resemble eczema or other common skin conditions.

Because of that resemblance, diagnosis often requires a skin biopsy, and sometimes more than one biopsy over time. Sézary syndrome typically involves the blood as well as the skin.

This diagnostic difficulty is part of why the litigation’s timeline questions are complicated, and why your dermatology and pathology records will be central to any review of your situation. Published research on dupilumab and lymphoma can be searched on PubMed; reported findings in that literature describe associations and case observations, not established causation.

What Early-Stage Litigation Means for You

An MDL at the leadership stage has not yet produced the evidence that later stages will. In practical terms:

• There is no settlement program, and no one can responsibly estimate what, if anything, any claim may be worth
• Timelines are unknown. MDLs commonly take years, and early schedules often change
• Deadlines still apply. Statutes of limitations vary by state and may run from diagnosis or discovery, so waiting for the litigation to mature can carry risk

If you are taking Dupixent now, do not stop or change your treatment without speaking to your prescribing doctor. Questions about side effects can also be reported to the FDA through its MedWatch program.

Records Worth Gathering Now

You do not need to have everything in hand to ask for a review, but these records tend to matter:

• Pharmacy and prescription records showing when Dupixent was started and stopped
• Dermatology notes describing your skin condition before and during treatment
• Biopsy and pathology reports, including any earlier biopsies read as eczema or dermatitis
• Oncology records confirming a CTCL, mycosis fungoides, or Sézary syndrome diagnosis

An attorney can request records you do not have.

Take the Next Step

If you or a family member used Dupixent for eczema or atopic dermatitis and were later diagnosed with cutaneous T-cell lymphoma, mycosis fungoides, or Sézary syndrome, or were diagnosed before treatment and believe the diagnosis may have been delayed, you can learn more on our Dupixent lymphoma page.

When you are ready, request a free case review. There is no cost to have your situation reviewed, and no obligation to proceed.